BRIEF published on 04/23/2026 at 15:15, 13 days 17 hours ago Newron Pharmaceuticals annonce les résultats de son assemblée générale annuelle 2026 Newron Pharmaceuticals Evenamide Membres Du Conseil D'administration Assemblée Générale Annuelle 2026 Xadago®
BRIEF published on 04/23/2026 at 15:15, 13 days 17 hours ago Newron Pharmaceuticals Announces AGM 2026 Results Board Members Newron Pharmaceuticals Evenamide AGM 2026 Xadago®
PRESS RELEASE published on 04/23/2026 at 15:10, 13 days 17 hours ago Newron announces AGM 2026 results Newron Pharmaceuticals S.p.A. announces successful AGM 2026 results including new Board members. Focus on developing therapies for nervous system diseases Board Members Newron Pharmaceuticals Thérapies AGM 2026 Nervous System Diseases
BRIEF published on 03/24/2026 at 07:05, 1 month 14 days ago Newron annonce ses résultats pour 2025 et ses perspectives pour 2026. Résultats Financiers Traitement De La Schizophrénie Perspectives Pour 2026 Brevet Accordé Essais Sur L'Evenamide
BRIEF published on 03/24/2026 at 07:05, 1 month 14 days ago Newron Announces 2025 Results and 2026 Outlook Financial Results Schizophrenia Treatment Patent Grant 2026 Outlook Evenamide Trials
PRESS RELEASE published on 03/24/2026 at 07:00, 1 month 14 days ago Newron presents 2025 financial results and provides 2026 outlook Newron Pharmaceuticals S.p.A. presents 2025 financial results and 2026 outlook, including progress on evenamide clinical trials and IP expansion Financial Results Clinical Trials Newron Pharmaceuticals 2026 Outlook IP Expansion
BRIEF published on 03/20/2026 at 07:05, 1 month 18 days ago Newron Pharmaceuticals to Present at SIRS 2026 Newron Pharmaceuticals Evenamide Treatment-resistant Schizophrenia Glutamate Modulation Schizophrenia Research
BRIEF published on 03/20/2026 at 07:05, 1 month 18 days ago Newron Pharmaceuticals présentera ses travaux au SIRS 2026 Newron Pharmaceuticals Evenamide Schizophrénie Résistante Au Traitement Modulation Du Glutamate Recherche Sur La Schizophrénie
PRESS RELEASE published on 03/20/2026 at 07:00, 1 month 18 days ago Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) Newron Pharmaceuticals S.p.A. to present at SIRS 2026 Congress on glutamatergic modulation in treatment-resistant schizophrenia Schizophrenia Newron Pharmaceuticals Congress Glutamatergic Modulation SIRS
BRIEF published on 03/19/2026 at 07:05, 1 month 19 days ago Newron Pharmaceuticals Extends Loan Repayment with EIB European Investment Bank Newron Pharmaceuticals Evenamide Finance Contract ENIGMA-TRS Phase III
Published on 05/07/2026 at 05:40, 3 hours 13 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 6 hours 53 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 9 hours 23 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 9 hours 48 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 9 hours 53 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/07/2026 at 08:48, 5 minutes ago Finnvera’s Annual General Meeting: New members to Finnvera’s Board of Directors and Supervisory Board
Published on 05/07/2026 at 08:36, 17 minutes ago Cherry SE publishes results for the first quarter of 2026 – Operating profitability significantly improved
Published on 05/07/2026 at 08:30, 23 minutes ago L'UE mise sur une politique climatique axée sur le marché: allègement des péages et des normes CO₂ pour les poids lourds
Published on 05/07/2026 at 07:43, 1 hour 10 minutes ago ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 14 hours 53 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 14 hours 53 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 14 hours 53 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
